| David Harold Cole, LMFT | |
|
1612 Railroad Ave, Guntersville, AL 35976-1854 | |
| (256) 582-8880 | |
| (256) 582-8890 |
| Full Name | David Harold Cole |
|---|---|
| Gender | Male |
| Speciality | Marriage & Family Therapist |
| Location | 1612 Railroad Ave, Guntersville, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336403997 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | 371 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| David Harold Cole, LMFT 1612 Railroad Ave, P. O Box 1001, Guntersville, AL 35976-1854 Ph: (256) 582-8880 | David Harold Cole, LMFT 1612 Railroad Ave, Guntersville, AL 35976-1854 Ph: (256) 582-8880 |
News Archive
In the longest and largest randomized, controlled study of sensor-augmented insulin pump therapy in type 1 diabetes, adult and pediatric patients using the Medtronic MiniMed Paradigm® REAL-Time System achieved better glucose control without an increase in hypoglycemia compared to multiple daily insulin injections (MDI), the most common approach to care today.
What causes brain damage and inflammation in severe cases of Gaucher disease? Little is known about the events that lead to brain pathology in some forms of the disease, and there is currently no treatment available - a bleak outlook for sufferers and their families. Now, scientists at the Weizmann Institute of Science have discovered a new cellular pathway implicated in Gaucher disease.
BioSante Pharmaceuticals, Inc. today announced that it will present a LibiGel clinical trial update at the 21st Annual Meeting of The North American Menopause Society (NAMS) being held from October 6-9, 2010 at the Sheraton Chicago Hotel & Towers in Chicago, Illinois.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products today announced results of the pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the nonsurgical treatment of Dupuytren's disease, was published in today's edition of the New England Journal of Medicine.
Researchers from Singapore-MIT Alliance for Research and Technology, MIT's research enterprise in Singapore, have discovered a new anti-phage defense mechanism found in some bacteria, which uses previously unknown features to protect their DNA.
› Verified 5 days ago
Ms. Bernette Rochella Harris, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 2409 Homer Clayton Drive, Guntersville, AL 35976 Phone: 256-582-4240 Fax: 256-582-4161 |